InterMune Gets Ready To Go Commercial With Esbriet Launch In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
InterMune plans to launch the first drug for IPF in Europe in September, and has initiated a new Phase III trial with the aim of securing U.S. approval in 2014.